Aims We aim to determine the optimal dose of dabigatran in Korean patients with atrial
fibrillation (AF). Methods and results We analysed 1834 patients with non-valvular AF …

Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an
international multicenter study (18,113 patients from 967 centers in 44 countries) that …

Background In “real-world” practice, anticoagulant therapy is indicated for patients whose
clinical profiles are not addressed in randomized clinical trials. We assessed the …

Background: Dabigatran is a kind of oral anticoagulant and there was little review only about
dabigatran and warfarin used in patients with atrial fibrillation. This meta-analysis only …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

In the RE-LY trial dabigatran 150 mg twice daily (D150) showed significantly fewer strokes,
and 110 mg (D110) significantly fewer major bleeding events (MBE) compared to well …

Background: Few data exist regarding frequency and predictors of bleeding complications
associated with anticoagulant therapy using dabigatran in Japanese patients with atrial …

Background—During follow-up of between 1 and 3 years in the Randomized Evaluation of
Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were …

Background Dabigatran, an oral direct thrombin inhibitor, possesses several advantages
over warfarin that can in principle simplify the management of stroke prevention in atrial …

Background: Dabigatran is an oral direct thrombin inhibitor recently approved for stroke
prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of …